TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma

Horlad,Hasita; Ohnishi,Koji; Ma,Chaoya; Fujiwara,Yukio; Niino,Daisuke; Ohshima,Koichi; Jinushi,Masahisa; Matsuoka,Masao; Takeya,Motohiro; Komohara,Yoshihiro

doi:10.3892/ol.2016.4774

August-2016 Volume 12 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

August-2016 Volume 12 Issue 2

Full Size Image

Article

TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma

Authors:
- Hasita Horlad
- Koji Ohnishi
- Chaoya Ma
- Yukio Fujiwara
- Daisuke Niino
- Koichi Ohshima
- Masahisa Jinushi
- Masao Matsuoka
- Motohiro Takeya
- Yoshihiro Komohara
View Affiliations / Copyright

Affiliations: Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto 860‑8556, Japan, Department of Pathology, School of Medicine, Kurume University, Kurume, Fukuoka 839‑0851, Japan, Institute for Advanced Medical Research, Graduate School of Medicine, Keio University, Tokyo 108‑8345, Japan, Institute for Virus Research, Kyoto University, Kyoto 606-8501, Japan
Pages: 1519-1524
|
Published online on: June 23, 2016

https://doi.org/10.3892/ol.2016.4774
Expand metrics +

Abstract

Adult T-cell leukemia/lymphoma (ATLL), an aggressive type of malignant lymphoma, is highly resistant to chemotherapy. However, the detailed mechanisms of the chemoresistance of ATLL have never been elucidated. We previously demonstrated that direct cell‑cell interaction between macrophages and lymphoma cells was significantly associated with lymphoma progression in patients with ATLL. The present study aimed to further analyze the effects of cell‑cell interaction between macrophages and ATLL cells by means of cell culture studies and immunohistochemical analysis using human ATLL samples. It was found that direct co‑culture with macrophages induced chemoresistance in the ATLL ATN‑1 cell line, but not in other cell lines, including TL-Mor, ED and ATL-2S. It was also found that expression of the T cell Ig and mucin domain‑containing molecule‑3 (TIM‑3) was induced in ATN‑1 cells by their long‑term co‑culture with macrophages. TIM‑3 gene transfection induced chemoresistance in the ATN‑1 cells. Immunostaining of ATLL tissues showed TIM‑3 expression in 25 out of 58 ATLL cases. Although TIM‑3 expression was not associated with overall survival or T classification, it was associated with resistance to chemotherapy. TIM‑3 expression is therefore considered to be a marker for predicting the efficacy of chemotherapy, and TIM‑3‑associated signals may be a therapeutic target for patients with ATLL.

View Figures

View References

1	Shirono K, Hattori T, Hata H, Nishimura H and Takatsuki K: Profiles of expression of activated cell antigens on peripheral blood and lymph node cells from different clinical stages of adult T-cell leukemia. Blood. 73:1664–1671. 1989.PubMed/NCBI
2	Ohshima K: Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci. 98:772–778. 2007. View Article : Google Scholar : PubMed/NCBI
3	Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984–87). Br J Haematol. 79:428–437. 1991. View Article : Google Scholar : PubMed/NCBI
4	Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, Manning S, Greenfield EA, Coyle AJ, Sobel RA, et al: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 415:536–541. 2002. View Article : Google Scholar : PubMed/NCBI
5	Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, et al: Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 13:832–842. 2012. View Article : Google Scholar : PubMed/NCBI
6	Tang D and Lotze MT: Tumor immunity times out: TIM-3 and HMGB1. Nat Immunol. 13:808–810. 2012. View Article : Google Scholar : PubMed/NCBI
7	Wiener Z, Kohalmi B, Pocza P, Jeager J, Tolgyesi G, Toth S, Gorbe E, Papp Z and Falus A: TIM-3 is expressed in melanoma cells and is upregulated in TGF-beta stimulated mast cells. J Invest Dermatol. 127:906–914. 2007. View Article : Google Scholar : PubMed/NCBI
8	Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G and Zou W: Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 56:1342–1351. 2012. View Article : Google Scholar : PubMed/NCBI
9	Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, Zhang X and Ma C: Ectopic expression of TIM-3 in lung cancers: A potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol. 137:978–985. 2012. View Article : Google Scholar : PubMed/NCBI
10	Komohara Y, Morita T, Annan DA, Horlad H, Ohnishi K, Yamada S, Nakayama T, Kitada S, Suzu S, Kinoshita I, et al: The coordinated actions of TIM-3 on cancer and myeloid cells in the regulation of tumorigenicity and clinical prognosis in clear cell renal cell carcinomas. Cancer Immunol Res. 3:999–1007. 2015. View Article : Google Scholar : PubMed/NCBI
11	Komohara Y, Niino D, Saito Y, Ohnishi K, Horlad H, Ohshima K and Takeya M: Clinical significance of CD163* tumor-associated macrophages in patients with adult T-cell leukemia/lymphoma. Cancer Sci. 104:945–951. 2013. View Article : Google Scholar : PubMed/NCBI
12	Takeda S, Maeda M, Morikawa S, Taniguchi Y, Yasunaga J, Nosaka K, Tanaka Y and Matsuoka M: Genetic and epigenetic inactivation of tax gene in adult T-cell leukemia cells. Int J Cancer. 109:559–567. 2004. View Article : Google Scholar : PubMed/NCBI
13	Komohara Y, Jinushi M and Takeya M: Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 105:1–8. 2014. View Article : Google Scholar : PubMed/NCBI
14	Komohara Y, Niino D, Ohnishi K, Ohshima K and Takeya M: Role of tumor-associated macrophages in hematological malignancies. Pathol Int. 65:170–176. 2015. View Article : Google Scholar : PubMed/NCBI
15	Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, Wang Z, Liu Z, Li H, He J, et al: PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia. 27:702–710. 2013. View Article : Google Scholar : PubMed/NCBI
16	Tanaka Y, Fukudome K, Hayashi M, Takagi S and Yoshie O: Induction of ICAM-1 and LFA-3 by Tax1 of human T-cell leukemia virus type 1 and mechanism of down-regulation of ICAM-1 or LFA-1 in adult-T-cell-leukemia cell lines. Int J Cancer. 60:554–561. 1995. View Article : Google Scholar : PubMed/NCBI
17	Huang YH, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, Dougan SK, Petersen BS, Melum E, Pertel T, et al: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 517:386–390. 2015. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

TIM-3 expression in lymphoma cells predicts chemoresistance in patients with adult T-cell leukemia/lymphoma

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Related Articles